Lab Information

Dr. Brian Ward

Senior Scientist
Centre for Translational Biology
Department of Medicine (McGill)

Research Profile

 Fundamental: 75%
 Clinical: 25%
 Epidemiology: 0%
 Evaluation: 0%
 This email address is being protected from spambots. You need JavaScript enabled to view it.
 EM3.3248
 E03.5383 (modules I, J, K, L)
 E03.5391 (modules M, N, O, P) /  #44591, #44585

Keywords

Vaccines • respiratory viruses • international health • parasitology • diagnostics

Research Interests

My research focuses on: the development and evaluation of novel virus-like particle vaccines (eg: influenza, measles) in both young and elderly subjects, international health issues with a particular focus on factors that influence HIV transmission, virus-nutritional interactions, and the development of new diagnostic tests for parasitic diseases. My laboratory sits at the junction between infectious diseases clinic and the basic science laboratory. Projects can start at either end of this spectrum and move from 'bed to the bench-top' or from 'bench-top to the bed'. Most of the basic work is carried out in Montreal with satellite facilities in Peru and Zimbabwe. Human vaccine studies are conducted at the MUHC Vaccine Study Centre in Pierrefonds, QC.


Team Members

Name Position
Hendin, Hilary PhD Student
Hubaishi, Fatima Hasan PhD Student
Winter, Kaitlin PhD Student
Hassan, Adam Sahl PhD Student
Labrie, Lydia Cassandra Susan PhD Student
Brewer, Angela Research Associate
Cyr, Louis Research Associate
Pillet, Stephane Research Associate
Beauchamp, Annie Laboratory Technician
Alyazidi, Raidan PhD Student
Allakhverdi, Zoulfia Research Associate
Du, Iris MSc Student
Koppula, Nikunz Research Assistant
Gravett, Jason MSc Student
Upadhyaya, Pavitra MSc Student
Mayar, Serena Undergraduate
Hanula, Ryan Undergraduate
Papadopoulos, Theodoros Undergraduate

Latest Publications

  1. Ward, B. J., Gobeil, P., Séguin, A., Atkins, J., Boulay, I., Charbonneau, P.-Y., Couture, M., D'Aoust, M.-A., Dhaliwall, J., Finkle, C., Hager, K., Mahmood, A., Makarkov, A., Cheng, M. P., Pillet, S., Schimke, P., St-Martin, S., Trépanier, S. & Landry, N. (2021). Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19. Nature medicine, vol. 27, p. 1071-1078.
  2. Vesikari, T., Langley, J. M., Segall, N., Ward, B. J., Cooper, C., Poliquin, G., Smith, B., Gantt, S., McElhaney, J. E., Dionne, M., van Damme, P., Leroux-Roels, I., Leroux-Roels, G., Machluf, N., Spaans, J. N., Yassin-Rajkumar, B., Anderson, D. E., Popovic, V., Diaz-Mitoma, F. & PROTECT Study Group (2021). Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial. The Lancet. Infectious diseases.
  3. Munoz, F. M., Cramer, J. P., Dekker, C. L., Dudley, M. Z., Graham, B. S., Gurwith, M., Law, B., Perlman, S., Polack, F. P., Spergel, J. M., Van Braeckel, E., Ward, B. J., Didierlaurent, A. M., Lambert, P. H. & Brighton Collaboration Vaccine-associated Enhanced Disease Working Group (2021). Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, vol. 39, p. 3053-3066.
  4. Ward, B. J., Séguin, A., Couillard, J., Trépanier, S. & Landry, N. (2021). Phase III: Randomized observer-blind trial to evaluate lot-to-lot consistency of a new plant-derived quadrivalent virus like particle influenza vaccine in adults 18-49 years of age. Vaccine, vol. 39, p. 1528-1533.
  5. Gomord, V., Stordeur, V., Fitchette, A.-C., Fixman, E. D., Tropper, G., Garnier, L., Desgagnes, R., Viel, S., Couillard, J., Beauverger, G., Trepout, S., Ward, B. J., van Ree, R., Faye, L. & Vézina, L.-P. (2020). Design, production and immunomodulatory potency of a novel allergen bioparticle. PloS one, vol. 15, p. e0242867.
  6. Ward, B. J., Makarkov, A., Séguin, A., Pillet, S., Trépanier, S., Dhaliwall, J., Libman, M. D., Vesikari, T. & Landry, N. (2020). Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials. Lancet (London, England), vol. 396, p. 1491-1503.
  7. Valerio, V., Bazan, M. C., Wang, M., Mazer, B. D., Pineau, C. A., Hazel, E. M., Bernatsky, S., Ward, B. J. & Colmegna, I. (2021). A multimodal intervention increases influenza vaccine uptake in rheumatoid arthritis. Clinical rheumatology, vol. 40, p. 575-579.
  8. Kane, P. B., Moyer, H., MacPherson, A., Papenburg, J., Ward, B. J., Broomell, S. B. & Kimmelman, J. (2020). Expert Forecasts of COVID-19 Vaccine Development Timelines. Journal of general internal medicine, vol. 35, p. 3753-3755.
  9. Gilbert, N. L., Rotondo, J., Shapiro, J., Sherrard, L., Fraser, W. D. & Ward, B. J. (2020). Corrigendum to "Seroprevalence of rubella antibodies and determinants of susceptibility to rubella in a cohort of pregnant women in Canada, 2008-2011" [Vaccine 35 (2017) 3050-3055]. Vaccine, vol. 38, p. 5387.
  10. Hassan, A. S., Zelt, N. H., Perera, D. J., Ndao, M. & Ward, B. J. (2019). Vaccination against the digestive enzyme Cathepsin B using a YS1646 Salmonella enterica Typhimurium vector provides almost complete protection against Schistosoma mansoni challenge in a mouse model. PLoS neglected tropical diseases, vol. 13, p. e0007490.
More on PubMed 



See also

Card image
Momar
Ndao


See profile
Card image
Michael
Libman


See profile
Card image
Inés
Colmegna


See profile
Card image
Sasha
Bernatsky


See profile
Card image
Christian
Pineau


See profile
Card image
Jesse
Papenburg


See profile

 

Latest News

Events/Seminars

Research groups

Careers